Drug intelligence / Profile preview

sytalizumab

Development stage: Phase 1
Lead developer: Therawisdom Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TWP-101 (sytalizumab) is a fully humanized agonistic anti-CD137 monoclonal IgG4 antibody developed for cancer immunotherapy. It targets a novel epitope of CD137 (also known as 4-1BB or TNFRSF9), acting as a CD137 agonist but not as a CD137 ligand antagonist. By stimulating CD137, TWP-101 serves as a potent co-stimulator of both adaptive and innate immune cells, enhancing antitumor immune responses. The drug is being evaluated in phase I clinical trials for advanced solid tumors, including melanoma and urothelial carcinoma[1][2][3].

Other names: sytalizumab

Targets

TNFRSF9 (CD137 extracellular domain)

Beyond the preview

Go deeper on sytalizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sytalizumab.

Explore the full profile